TABS Group Founder and CEO Dr. Kurt Jetta is featured in a recent Drug Store News article about the analgesics market:
External analgesics is a category replete with growth brands with a base of $497.8 million across total U.S. multi-outlets, and more than 8.1% in growth for the 52 weeks ended Sept. 7, according to IRI data.
Five of the top 10 external analgesic brands are growing at a greater than 20% clip. “They’re all up double digits, and they’re all holding their sales over an extended period of time,” noted Kurt Jetta, CEO TABS Group. “It’s not as if they got a big surge in distribution, and they’re now ready to anniversary their numbers.”
